Download Free Sample
Buy Now
Table of Content
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations in the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
6.1. Chapter Overview
6.2. mRNA Therapeutics
6.2.1. Advantages of mRNA Therapeutics
6.2.2. Key Applications of mRNA Therapeutics
6.3. mRNA Vaccines
6.3.1. Advantages of mRNA Vaccines
6.3.2. Key Applications of mRNA Vaccines
6.4. mRNA Delivery Routes
6.5. mRNA Delivery Strategies
6.6. Key Challenges Associated with mRNA Vaccines and Therapeutics
6.7. Future Perspectives
7.1. Chapter Overview
7.2. mRNA Vaccines and Therapeutics: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Drug Candidate
7.2.3. Analysis by Type of Program
7.2.4. Analysis by Type of Delivery System
7.2.5. Analysis by Type of Molecule Encoded
7.2.6. Analysis by Route of Administration
7.2.7. Analysis by Therapeutic Area
7.3. mRNA Vaccines and Therapeutics: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Most Active Developers: Analysis by Number of Drugs Developed
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. mRNA Vaccines and Therapeutics: Product Competitiveness Analysis
8.4.1. mRNA Vaccines and Therapeutics Developed by Players based in North America
8.4.2. mRNA Vaccines and Therapeutics Developed by Players based in Europe
8.4.3. mRNA Vaccines and Therapeutics Developed by Players based in Asia-Pacific and Rest of the World
9.1. Chapter Overview
9.2. Leading Developers in mRNA Vaccines and Therapeutics Market based in North America
9.2.1. Arcturus Therapeutics
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. mRNA Vaccines and Therapeutics Portfolio
9.2.1.4. Recent Developments and Future Outlook
9.2.2. Immorna
9.2.2.1. Company Overview
9.2.2.2. mRNA Vaccines and Therapeutics Portfolio
9.2.2.3. Recent Developments and Future Outlook
9.2.3. Moderna
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. mRNA Vaccines and Therapeutics Portfolio
9.2.3.4. Recent Developments and Future Outlook
9.2.4. Providence Therapeutics
9.2.4.1. Company Overview
9.2.4.2. Financial Information
9.2.4.3. mRNA Vaccines and Therapeutics Portfolio
9.2.4.4. Recent Developments and Future Outlook
9.2.5. Innovac Therapeutics
9.2.5.1. Company Overview
9.2.5.2. mRNA Vaccines and Therapeutics Portfolio
9.2.5.3. Recent Developments and Future Outlook
9.2.6. Kernal Biologics
9.2.6.1. Company Overview
9.2.6.2. Financial Information
9.2.6.3. mRNA Vaccines and Therapeutics Portfolio
9.2.6.4. Recent Developments and Future Outlook
9.2.7. Recode Therapeutics
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. mRNA Vaccines and Therapeutics Portfolio
9.2.7.4. Recent Developments and Future Outlook
9.2.8. Rejuvenation Technologies
9.2.8.1. Company Overview
9.2.8.2. Financial Information
9.2.8.3. mRNA Vaccines and Therapeutics Portfolio
9.2.8.4. Recent Developments and Future Outlook
9.2.9. RNAimmune
9.2.9.1. Company Overview
9.2.9.2. Financial Information
9.2.9.3. mRNA Vaccines and Therapeutics Portfolio
9.2.9.4. Recent Developments and Future Outlook
9.2.10. Turn Biotechnologies
9.2.10.1. Company Overview
9.2.10.2. Financial Information
9.2.10.3. mRNA Vaccines and Therapeutics Portfolio
9.2.10.4. Recent Developments and Future Outlook
9.2.11. Strand Therapeutics
9.2.11.1. Company Overview
9.2.11.2. Financial Information
9.2.11.3. mRNA Vaccines and Therapeutics Portfolio
9.2.11.4. Recent Developments and Future Outlook
10.1. Chapter Overview
10.2. Leading Developers in mRNA Vaccines and Therapeutics Market based in North America
10.2.1. BioNTech
10.2.1.1. Company Overview
10.2.1.2. Financial Information
10.2.1.3. mRNA Vaccines and Therapeutics Portfolio
10.2.1.4. Recent Developments and Future Outlook
10.2.2. CureVac
10.2.2.1. Company Overview
10.2.2.2. Financial Information
10.2.2.3. mRNA Vaccines and Therapeutics Portfolio
10.2.2.4. Recent Developments and Future Outlook
10.2.3. Ethris
10.2.3.1. Company Overview
10.2.3.2. mRNA Vaccines and Therapeutics Portfolio
10.2.3.3. Recent Developments and Future Outlook
11.1. Chapter Overview
11.2. Leading Developers in mRNA Vaccines and Therapeutics Market based in North America
11.2.1. Suzhou Abogen Biosciences
11.2.1.1. Company Overview
11.2.1.2. mRNA Vaccines and Therapeutics Portfolio
11.2.1.3. Recent Developments and Future Outlook
11.2.2. Gennova Biopharmaceuticals
11.2.2.1. Company Overview
11.2.2.2. Financial Information
11.2.2.3. mRNA Vaccines and Therapeutics Portfolio
11.2.2.4. Recent Developments and Future Outlook
11.2.3. RNACure
11.2.3.1. Company Overview
11.2.3.2. mRNA Vaccines and Therapeutics Portfolio
11.2.3.3. Recent Developments and Future Outlook
11.2.4. Walvax
11.2.4.1. Company Overview
11.2.4.2. Financial Information
11.2.4.3. mRNA Vaccines and Therapeutics Portfolio
11.2.4.4. Recent Developments and Future Outlook
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. mRNA Vaccines and Therapeutics Market: Big Player Initiatives
12.3.1. Analysis by Year of Initiative
12.3.2. Analysis by Type of Initiative
12.3.3. Analysis by Year and Type of Initiative
12.3.4. Analysis by Type of Partnership
12.3.5. Analysis by Type of Expansion
12.3.6. Analysis by Year of Initiative and Company
12.3.7. Big Pharma Players: Analysis by Number of Initiatives
12.4. Benchmarking Analysis: Big Pharma Players
12.4.1. Spider Web Analysis: Bayer
12.4.2. Spider Web Analysis: Pfizer
12.4.3. Spider Web Analysis: Sanofi
12.5. Concluding Remarks
13.1. Chapter Overview
13.2. Start-ups focused on mRNA Vaccines and Therapeutics
13.3. Benchmarking of Start-ups
13.4. Startup-Health Indexing
13.4.1. Analysis by Location of Headquarters
13.4.2. Analysis by Company Strength
13.4.3. Analysis by Pipeline Maturity
13.4.4. Analysis by Pipeline Strength
13.4.5. Analysis by Financial Support
13.4.6. Analysis by Investor Strength
13.4.7. Analysis by Partnership Activity
13.4.8. Start-ups Health Indexing: Roots Analysis Perspective
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. mRNA Vaccines and Therapeutics: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
14.3.3. Analysis by Trial Phase
14.3.4. Analysis of Number of Patients Enrolled by Trial Phase
14.3.5. Analysis by Trial Status
14.3.6. Analysis by Trial Registration Year and Trial Status
14.3.7. Analysis by Patient Gender
14.3.8. Analysis by Study Design
14.3.8.1. Analysis by Type of Allocation
14.3.8.2. Analysis by Type of Intervention Model
14.3.8.3. Analysis by Type of Masking
14.3.8.4. Analysis by Trial Purpose
14.3.9. Analysis by Type of Sponsor / Collaborator
14.3.10. Analysis by Geography
14.3.10.1. Analysis of Clinical Trials by Geography
14.3.10.2. Analysis of Clinical Trials by Geography and Trial Status
14.3.10.3. Analysis of Patients Enrolled by Geography and Trial Status
15.1. Chapter Overview
15.2. Partnership Models
15.3. mRNA Vaccines and Therapeutics Market: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Therapeutic Area
15.3.5. Most Active Players: Analysis by Number of Partnerships
15.3.6. Analysis by Geography
15.3.6.1. Intercontinental and Intracontinental Agreements
15.3.6.2. Local and International Agreements
16.1. Chapter Overview
16.2. Funding Models
16.3. mRNA Vaccines and Therapeutics Market: Funding and Investment Analysis
16.3.1. Analysis by Year of Funding
16.3.1.1. Cumulative Year-wise Trend of Funding Instances
16.3.1.2. Cumulative Year-wise Trend of Amount Invested
16.3.2. Analysis by Type of Funding
16.3.2.1. Analysis of Funding Instances
16.3.2.2. Analysis of Amount Invested
16.3.3. Analysis by Year and Type of Funding
16.3.4. Analysis by Amount Raised by Year and Type of Funding
16.3.5. Analysis by Therapeutic Area
16.3.6. Most Active Players: Analysis by Number of Funding Instances
16.3.7. Most Active Players: Analysis by Amount Raised
16.3.8. Analysis by Geography
16.3.9. Most Active Players: Analysis by Number of Funding Instances
16.3.10. Most Active Players: Analysis by Amount Invested
16.4. Summary of Funding and Investments
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. mRNA Vaccines and Therapeutics: Patent Analysis
17.3.1. Analysis by Type of Patent
17.3.2. Analysis by Patent Publication Year
17.3.3. Analysis by Type of Patent and Publication Year
17.3.4. Analysis by Patent Application Year
17.3.5. Analysis by Patent Jurisdiction
17.3.6. Analysis by CPC Symbols
17.3.7. Analysis by Type of Applicant
17.3.8. Leading Industry Players: Analysis by Number of Patents
17.3.9. Leading Non-Industry Players: Analysis by Number of Patents
17.3.10. Leading Inventors: Analysis by Number of Patents
17.4. Patent Benchmarking Analysis
17.4.1. Analysis of Patent Characteristics
17.5. Patent Valuation
17.6. Leading Patents by Number of Citations
18.1. Chapter Overview
18.2. Methodology
18.3. Key Parameters
18.4. General Reasons for Failure of Trials Focused on mRNA Vaccines and Therapeutics
18.5. Benchmarking Analysis: Distribution of Key Strategies by mRNA Vaccines and Therapeutics
19.1. Chapter Overview
19.2. Outsourcing: Go / No-Go Framework
19.3. mRNA Vaccines and Therapeutics Outsourcing: Go / No-Go Framework
19.3.1. Key Parameters and Assumptions
19.3.2. Methodology
19.3.3. Results and Interpretations
19.3.3.1. Outsourcing: Go / No-Go Framework for Small Companies
19.3.3.2. Outsourcing: Go / No-Go Framework for Mid-Sized Companies
19.3.3.3. Outsourcing: Go / No-Go Framework for Large Companies
20.1. Chapter Overview
20.2. Market Drivers
20.3. Market Restraints
20.4. Market Opportunities
20.5. Market Challenges
20.6. Conclusion
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Global mRNA Vaccines and Therapeutics Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.3.1. Scenario Analysis
21.3.1.1. Conservative Scenario
21.3.1.2. Optimistic Scenario
21.4. Key Market Segmentations
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. mRNA Vaccines and Therapeutics Market: Distribution by Application Area
22.3.1. mRNA Vaccines and Therapeutics Market for COVID-19, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.3.2. mRNA Vaccines and Therapeutics Market for Other Indications, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. mRNA Vaccines and Therapeutics Market: Distribution by Target Disease Indication
23.3.1. mRNA Vaccines and Therapeutics Market for Cystic Fibrosis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.2. mRNA Vaccines and Therapeutics Market for Influenza, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.3. mRNA Vaccines and Therapeutics Market for Melanoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.4. mRNA Vaccines and Therapeutics Market for Metastatic/ R/R Head and Neck cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.5. mRNA Vaccines and Therapeutics Market for Mononucleosis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.6. mRNA Vaccines and Therapeutics Market for Muscle-Invasive Urothelial Carcinoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.7. mRNA Vaccines and Therapeutics Market for Non-Small Cell Lung Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.8. mRNA Vaccines and Therapeutics Market for Norovirus Acute Gastroenteritis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.9. mRNA Vaccines and Therapeutics Market for Propionic Acidemia, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.3.10. mRNA Vaccines and Therapeutics Market for RSV Infection, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.4. Data Triangulation and Validation
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. mRNA Vaccines and Therapeutics Market: Distribution by Geographical Regions
24.3.1. mRNA Vaccines and Therapeutics Market in North America, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.1.1. mRNA Vaccines and Therapeutics Market in the US, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.1.2. mRNA Vaccines and Therapeutics Market in Canada, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.2. mRNA Vaccines and Therapeutics Market in Europe, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.2.1. mRNA Vaccines and Therapeutics Market in UK, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.2.2. mRNA Vaccines and Therapeutics Market in the Germany, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.2.3. mRNA Vaccines and Therapeutics Market in Spain, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.2.4. mRNA Vaccines and Therapeutics Market in Italy, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.2.5. mRNA Vaccines and Therapeutics Market in France, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.2.6. mRNA Vaccines and Therapeutics Market in Rest of Europe, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.3. mRNA Vaccines and Therapeutics Market in Aisa-Pacific, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.3.1. mRNA Vaccines and Therapeutics Market in China, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.3.2. mRNA Vaccines and Therapeutics Market in India, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.3.3. mRNA Vaccines and Therapeutics Market in Japan, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.3.4. mRNA Vaccines and Therapeutics Market in Australia, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.3.4. Penetration Growth (P-G) Matrix
24.3.5. Market Movement Analysis
24.4. Data Triangulation and Validation
25.1. mRNA Vaccines and Therapeutics Market in North America: Distribution by Application Area
25.1.1. mRNA Vaccines and Therapeutics Market in North America for COVID-19, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.1.2. mRNA Vaccines and Therapeutics Market in North America for Other Indications, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.2. mRNA Vaccines and Therapeutics Market in North America: Distribution by Target Disease Indication
25.2.1. mRNA Vaccines and Therapeutics Market in North America for Cystic Fibrosis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.2.2. mRNA Vaccines and Therapeutics Market in North America for Influenza, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.2.3. mRNA Vaccines and Therapeutics Market in North America for Melanoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.2.4. mRNA Vaccines and Therapeutics Market in North America for Metastatic/ R/R Head and Neck cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.2.5. mRNA Vaccines and Therapeutics Market in North America for Mononucleosis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.2.6. mRNA Vaccines and Therapeutics Market in North America for Muscle-Invasive Urothelial Carcinoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.2.7. mRNA Vaccines and Therapeutics Market in North America for Non-Small Cell Lung Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.2.8. mRNA Vaccines and Therapeutics Market in North America for Norovirus Acute Gastroenteritis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.2.9. mRNA Vaccines and Therapeutics Market in North America for Propionic Acidemia, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.2.10. mRNA Vaccines and Therapeutics Market in North America for RSV Infection, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.1. mRNA Vaccines and Therapeutics Market in Europe: Distribution by Application Area
26.1.1. mRNA Vaccines and Therapeutics Market in Europe for COVID-19, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.1.2. mRNA Vaccines and Therapeutics Market in Europe for Other Indications, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.2. mRNA Vaccines and Therapeutics Market in Europe: Distribution by Target Disease Indication
26.2.1. mRNA Vaccines and Therapeutics Market in Europe for Cystic Fibrosis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.2.2. mRNA Vaccines and Therapeutics Market in Europe for Influenza, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.2.3. mRNA Vaccines and Therapeutics Market in Europe for Melanoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.2.4. mRNA Vaccines and Therapeutics Market in Europe for Metastatic/ R/R Head and Neck cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.2.5. mRNA Vaccines and Therapeutics Market in Europe for Mononucleosis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.2.6. mRNA Vaccines and Therapeutics Market in Europe for Muscle-Invasive Urothelial Carcinoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.2.7. mRNA Vaccines and Therapeutics Market in Europe for Non-Small Cell Lung Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.2.8. mRNA Vaccines and Therapeutics Market in Europe for Norovirus Acute Gastroenteritis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.2.9. mRNA Vaccines and Therapeutics Market in Europe for Propionic Acidemia, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.2.10. mRNA Vaccines and Therapeutics Market in Europe for RSV Infection, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.1. mRNA Vaccines and Therapeutics Market in Asia Pacific: Distribution by Application Area
27.1.1. mRNA Vaccines and Therapeutics Market in Asia Pacific for COVID-19, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.1.2. mRNA Vaccines and Therapeutics Market in Asia Pacific for Other Indications, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.2. mRNA Vaccines and Therapeutics Market in Asia Pacific: Distribution by Target Disease Indication
27.2.1. mRNA Vaccines and Therapeutics Market in Asia Pacific for Cystic Fibrosis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.2.2. mRNA Vaccines and Therapeutics Market in Asia Pacific for Influenza, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.2.3. mRNA Vaccines and Therapeutics Market in Asia Pacific for Melanoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.2.4. mRNA Vaccines and Therapeutics Market in Asia Pacific for Metastatic/ R/R Head and Neck cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.2.5. mRNA Vaccines and Therapeutics Market in Asia Pacific for Mononucleosis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.2.6. mRNA Vaccines and Therapeutics Market in Asia Pacific for Muscle-Invasive Urothelial Carcinoma, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.2.7. mRNA Vaccines and Therapeutics Market in Asia Pacific for Non-Small Cell Lung Cancer, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.2.8. mRNA Vaccines and Therapeutics Market in Asia Pacific for Norovirus Acute Gastroenteritis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.2.9. mRNA Vaccines and Therapeutics Market in Asia Pacific for Propionic Acidemia, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.2.10. mRNA Vaccines and Therapeutics Market in Asia Pacific for RSV Infection, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
29.1. Chapter Overview
29.2. Company A
29.2.1. Company Snapshot
29.2.2. Interview Transcript: Business Development Manager
29.3. Company B
29.3.1. Company Snapshot
29.3.2. Interview Transcript: Senior Director, Business Development
29.4. Company C
29.4.1. Company Snapshot
29.4.2. Interview Transcript: Team Leader
29.5. Company D
29.5.1. Company Snapshot
29.5.2. Interview Transcript: Chief Executive Officer
29.6. Company E
29.6.1. Company Snapshot
29.6.2. Interview Transcript: President
29.7. Company F
29.7.1. Company Snapshot
29.7.2. Interview Transcript: Medical Professional
29.8. Company G
29.8.1. Company Snapshot
29.8.2. Interview Transcript: Chief Executive Officer
29.9. Company H
29.9.1. Company Snapshot
29.9.2. Interview Transcript: Director of Advanced Drug Delivery
Figure 2.1 Research Methodology: Project Methodology
Figure 7.1 mRNA Vaccines and Therapeutics Developers: Distribution by Most Active Developers
Figure 9.1 Arcturus Therapeutics: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 9.2 Moderna: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 9.3 Providence Therapeutics: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 9.4 Kernal Biologics: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 9.5 Recode Therapeutics: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 9.6 Rejuvenation Technologies: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 9.7 RNAimmune: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 9.8 Turn Biotechnologies: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 9.9 Strand Therapeutics: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 10.1 BioNTech: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 10.2 CureVac: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 11.1 Gennova Biopharmaceuticals: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 11.2 Walvax: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Figure 12.1 Big Pharma Initiatives: Distribution by Year of Initiative
Figure 13.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 13.2 Startup-Health Indexing: Distribution by Company Strength
Figure 13.3 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 13.4 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 13.5 Startup-Health Indexing: Distribution by Financial Support
Figure 13.6 Startup-Health Indexing: Distribution by Investor Strength
Figure 13.7 Startup-Health Indexing: Distribution by Partnership Activity
Figure 13.8 Startup-Health Indexing: Roots Analysis Perspective
Figure 14.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 14.2 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 14.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 14.4 Clinical Trial Analysis: Distribution by Analysis of Number of Patients Enrolled by Trial Status
Figure 14.5 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 14.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 14.7 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year
Figure 14.8 Clinical Trial Analysis: Distribution by Study Design
Figure 14.9 Clinical Trial Analysis: Distribution of Leading Industry Players: Analysis by Number of Clinical Trials
Figure 14.10 Clinical Trial Analysis: Distribution by Patient Gender
Figure 14.11 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 14.12 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 14.13 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 14.14 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 14.15 Clinical Trial Analysis: Distribution by Number of Clinical Trials in Geography
Figure 14.16 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Geography
Figure 15.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 15.5 Partnerships and Collaborations: Most Active Players: Distribution by Number of Partnerships
Figure 15.6 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 15.7 Partnerships and Collaborations: Local and International Agreements
Figure 16.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Pre-2020-2025
Figure 16.2 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Pre-2020-2025 (USD Million)
Figure 16.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Figure 16.4 Funding and Investment Analysis: Distribution of Amount Raised by Year and Type of Funding
Figure 16.5 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 16.6 Funding and Investment Analysis: Most Active Players: Distribution by Number of Funding Instances
Figure 16.7 Funding and Investment Analysis: Most Active Players: Distribution by Amount Raised
Figure 16.8 Funding and Investment Analysis: Geographical Distribution by Number of Instances
Figure 16.9 Funding and Investment Analysis: Geographical Distribution by Number of Instances by Amount Raised
Figure 17.1 Patent Analysis: Distribution by Type of Patent
Figure 17.2 Patent Analysis: Distribution by Patent Publication Year
Figure 17.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 17.4 Patent Analysis: Distribution by Application Year
Figure 17.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 17.6 Patent Analysis: Distribution by CPC Symbols
Figure 17.7 Patent Analysis: Distribution by Type of Applicant
Figure 17.8 Patent Analysis: Distribution of Leading Industry Players: Analysis by Number of Patents
Figure 17.9 Patent Analysis: Distribution of Leading Non-Industry Players: Analysis by Number of Patents
Figure 17.10 Patent Analysis: Distribution of Leading Inventors: Analysis by Number of Patents
Figure 17.11 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 17.12 Patent Analysis: Patent Valuation
Figure 18.1 FDA Approval Strategies: Distribution of Key Strategies by Vaccines
Figure 19.1 Outsourcing: Go / No-Go Framework
Figure 19.2 Outsourcing: Go / No-Go Framework Methodology
Figure 19.3 Outsourcing: Go / No-Go Framework for Cell and Gene Therapy Developers
Figure 19.4 Outsourcing: Go / No-Go Framework for Small Companies
Figure 19.5 Outsourcing: Go / No-Go Framework for Mid-sized Companies
Figure 19.6 Outsourcing: Go / No-Go Framework for Large Companies
Figure 20.1 mRNA Vaccine and Therapeutics: Market Drivers
Figure 24.1 mRNA Vaccine and Therapeutics Market: Distribution by Geographical Regions, 2020, 2024 and 2035
Figure 24.2 mRNA Vaccine and Therapeutics Market in North America, till 2035 (USD Million)
Figure 24.3 mRNA Vaccine and Therapeutics Market in the US, till 2035 (USD Million)
Figure 24.4 mRNA Vaccine and Therapeutics Market in Canada, till 2035 (USD Million)
Figure 24.5 mRNA Vaccine and Therapeutics Market in Europe, till 2035 (USD Million)
Figure 24.6 mRNA Vaccine and Therapeutics Market in Germany, till 2035 (USD Million)
Figure 24.7 mRNA Vaccine and Therapeutics Market in the UK, till 2035 (USD Million)
Figure 24.8 mRNA Vaccine and Therapeutics Market in France, till 2035 (USD Million)
Figure 24.9 mRNA Vaccine and Therapeutics Market in Italy, till 2035 (USD Million)
Figure 24.10 mRNA Vaccine and Therapeutics Market in Spain, till 2035 (USD Million)
Figure 24.11 mRNA Vaccine and Therapeutics Market in Belgium, till 2035 (USD Million)
Figure 24.12 mRNA Vaccine and Therapeutics Market in Asia-Pacific, till 2035 (USD Million)
Figure 24.13 mRNA Vaccine and Therapeutics Market in China, till 2035 (USD Million)
Figure 24.14 mRNA Vaccine and Therapeutics Market in India, till 2035 (USD Million)
Figure 24.15 mRNA Vaccine and Therapeutics Market in Japan, till 2035 (USD Million)
Figure 24.16 mRNA Vaccine and Therapeutics Market in Australia, till 2035 (USD Million)
Figure 30.1 Concluding Remarks: Overall Market Landscape
Table 7.1 mRNA Vaccines and Therapeutics: Overall Market Landscape
Table 9.1 Rejuvenation Technologies: Recent Developments and Future Outlook
Table 9.2 RNAimmune: Recent Developments and Future Outlook
Table 9.3 Turn Biotechnologies: Recent Developments and Future Outlook
Table 9.4 Strand Therapeutics: Recent Developments and Future Outlook
Table 10.1 BioNTech: Company Overview
Table 10.2 BioNTech: Pipeline Overview
Table 10.3 BioNTech: Recent Developments and Future Outlook
Table 10.4 CureVac: Company Overview
Table 10.5 CureVac: Pipeline Overview
Table 10.6 CureVac: Recent Developments and Future Outlook
Table 10.7 Ethris: Company Overview
Table 10.8 Ethris: Pipeline Overview
Table 10.9 Ethris: Recent Developments and Future Outlook
Table 11.1 Suzhou Abogen Biosciences: Company Overview
Table 11.2 Suzhou Abogen Biosciences: Pipeline Overview
Table 11.3 Suzhou Abogen Biosciences: Recent Developments and Future Outlook
Table 11.4 Gennova Biopharmaceuticals: Company Overview
Table 11.5 Gennova Biopharmaceuticals: Pipeline Overview
Table 11.6 Gennova Biopharmaceuticals: Recent Developments and Future Outlook
Table 11.7 RNACure: Company Overview
Table 11.8 RNACure: Pipeline Overview
Table 11.9 RNACure: Recent Developments and Future Outlook
Table 11.10 Walwax: Company Overview
Table 11.11 Walwax: Pipeline Overview
Table 11.12 Walwax: Recent Developments and Future Outlook
Table 32.1 mRNA Vaccines and Therapeutics: Distribution by Status of Development
Table 32.2 mRNA Vaccines and Therapeutics: Distribution by Type of Drug Candidate
Table 32.3 mRNA Vaccines and Therapeutics: Distribution by Type of Program
Table 32.4 mRNA Vaccines and Therapeutics: Distribution by Type of Delivery System
Table 32.5 mRNA Vaccines and Therapeutics: Distribution by Type of Molecule Encoded
Table 32.6 mRNA Vaccines and Therapeutics: Distribution by Route of Administration
Table 32.7 mRNA Vaccines and Therapeutics: Distribution by Therapeutic Area
Table 32.8 mRNA Vaccines and Therapeutics Developers: Distribution by Year of Establishment
Table 32.9 mRNA Vaccines and Therapeutics Developers: Distribution by Company Size
Table 32.10 mRNA Vaccines and Therapeutics Developers: Distribution by Location of Headquarters
Table 32.11 mRNA Vaccines and Therapeutics Developers: Distribution by Most Active Developers
Table 32.12 Product Competitiveness Analysis: mRNA Vaccines and Therapeutics Developers based in North America
Table 32.13 Product Competitiveness Analysis: mRNA Vaccines and Therapeutics Developers based in Europe
Table 32.14 Product Competitiveness Analysis: mRNA Vaccines and Therapeutics Developers based in Asia-Pacific and Rest of the World
Table 32.15 Arcturus Therapeutics: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.16 Moderna: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.17 Providence Therapeutics: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.18 Kernal Biologics: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.19 Recode Therapeutics: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.20 Rejuvenation Technologies: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.21 RNAimmune: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.22 Turn Biotechnologies: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.23 Strand Therapeutics: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.24 BioNTech: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.25 CureVac: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.26 Gennova Biopharmaceuticals: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.27 Walvax: Annual Revenues, 2021 – 9M 2025 (USD Billion)
Table 32.28 Big Pharma Initiatives: Distribution by Year of Initiative
Table 32.29 Big Pharma Initiatives: Distribution by Type of Initiative
Table 32.30 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Table 32.31 Big Pharma Initiatives: Distribution by Type of Partnership
Table 32.32 Big Pharma Initiatives: Distribution by Type of Expansion
Table 32.33 Big Pharma Initiatives: Distribution by Year of Initiative and Company
Table 32.34 Big Pharma Initiatives: Distribution by Number of Initiatives
Table 32.35 Spider Web Analysis: Bayer
Table 32.36 Spider Web Analysis: Pfizer
Table 32.37 Spider Web Analysis: Sanofi
Table 32.38 Startup-Health Indexing: Distribution by Location of Headquarters
Table 32.39 Startup-Health Indexing: Distribution by Company Strength
Table 32.40 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 32.41 Startup-Health Indexing: Distribution by Pipeline Strength
Table 32.42 Startup-Health Indexing: Distribution by Financial Support
Table 32.43 Startup-Health Indexing: Distribution by Investor Strength
Table 32.44 Startup-Health Indexing: Distribution by Partnership Activity
Table 32.45 Startup-Health Indexing: Roots Analysis Perspective
Table 32.46 Start-up Health Indexing: Leading Companies
Table 32.47 Clinical Trial Analysis: Distribution by Trial Status
Table 32.48 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 32.49 Clinical Trial Analysis: Distribution by Trial Phase
Table 32.50 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Status
Table 32.51 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 32.52 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 32.53 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year
Table 32.54 Clinical Trial Analysis: Distribution by Study Design
Table 32.55 Clinical Trial Analysis: Distribution of Leading Industry Players: Analysis by Number of Clinical Trials
Table 32.56 Clinical Trial Analysis: Distribution by Patient Gender
Table 32.57 Clinical Trial Analysis: Distribution by Target Patient Population
Table 32.58 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 32.59 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 32.60 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 32.61 Clinical Trial Analysis: Distribution by Number of Clinical Trials in Geography
Table 32.62 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Geography
Table 32.63 Partnerships and Collaborations: Distribution by Year of Partnership
Table 32.64 Partnerships and Collaborations: Distribution by Type of Partnership
Table 32.65 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 32.66 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 32.67 Partnerships and Collaborations: Most Active Players: Distribution by Number of Partnerships
Table 32.68 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 32.69 Partnerships and Collaborations: Local and International Agreements
Table 32.70 Funding and Investment Analysis: Cumulative Year-wise Trend, Pre-2020-2025
Table 32.71 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Pre-2020-2025 (USD Million)
Table 32.72 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Table 32.73 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 32.74 Funding and Investment Analysis: Distribution of Amount Raised by Year and Type of Funding
Table 32.75 Funding and Investment Analysis: Distribution by Therapeutic Area
Table 32.76 Funding and Investment Analysis: Most Active Players: Distribution by Number of Funding Instances
Table 32.77 Funding and Investment Analysis: Most Active Players: Distribution by Amount Raised
Table 32.78 Funding and Investment Analysis: Geographical Distribution by Number of Instances
Table 32.79 Funding and Investment Analysis: Geographical Distribution by Number of Instances by Amount Raised
Table 32.80 Patent Analysis: Distribution by Type of Patent
Table 32.81 Patent Analysis: Distribution by Patent Publication Year
Table 32.82 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 32.83 Patent Analysis: Distribution by Application Year
Table 32.84 Patent Analysis: Distribution by Patent Jurisdiction
Table 32.85 Patent Analysis: Distribution by Distribution by CPC Symbols
Table 32.86 Patent Analysis: Distribution by Distribution by Type of Applicant
Table 32.87 Patent Analysis: Distribution of Leading Industry Players: Analysis by Number of Patents
Table 32.88 Patent Analysis: Distribution of Leading Non-Industry Players: Analysis by Number of Patents
Table 32.89 Patent Analysis: Distribution of Leading Inventors: Analysis by Number of Patents
Table 32.90 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Table 32.91 Patent Analysis: Patent Valuation
Table 32.92 FDA Approval Strategies: Distribution of Key Strategies by Vaccines
Table 32.93 Outsourcing: Go / No-Go Framework
Table 32.94 Outsourcing: Go / No-Go Framework Methodology
Table 32.95 Outsourcing: Go / No-Go Framework for Cell and Gene Therapy Developers
Table 32.96 Outsourcing: Go / No-Go Framework for Small Companies
Table 32.97 Outsourcing: Go / No-Go Framework for Mid-sized Companies
Table 32.98 Outsourcing: Go / No-Go Framework for Large Companies
Table 32.99 mRNA Vaccines and Therapeutics: Market Drivers
Table 32.100 mRNA Vaccines and Therapeutics: Market Restraints
Table 32.101 mRNA Vaccines and Therapeutics: Market Opportunities
Table 32.102 mRNA Vaccines and Therapeutics: Market Challenges.
Table 32.103 Global mRNA Vaccines and Therapeutics Market, till 2035 (USD Million)
Table 32.104 Global mRNA Vaccines and Therapeutics Market, till 2035: Conservative Scenario (USD Million)
Table 32.105 Global mRNA Vaccines and Therapeutics Market, till 2035: Optimistic Scenario (USD Million)
Table 32.106 mRNA Vaccines and Therapeutics Market: Distribution by Application Area
Table 32.107 mRNA Vaccines and Therapeutics Market for COVID-19, till 2035 (USD Million)
Table 32.108 mRNA Vaccines and Therapeutics Market for Other Indications, till 2035 (USD Million)
Table 32.109 mRNA Vaccines and Therapeutics Market: Distribution by Target Disease Indication
Table 32.110 mRNA Vaccines and Therapeutics Market for Influenza, till 2035 (USD Million)
Table 32.111 mRNA Vaccines and Therapeutics Market for Respiratory Syncytial Virus Infection, till 2035 (USD Million)
Table 32.112 mRNA Vaccines and Therapeutics Market for Cytomegalovirus Disease, till 2035 (USD Million)
Table 32.113 mRNA Vaccines and Therapeutics Market: Distribution by Geographical Regions
Table 32.114 mRNA Vaccines and Therapeutics Market in North America, till 2035 (USD Million)
Table 32.115 mRNA Vaccines and Therapeutics Market in the US, till 2035 (USD Million)
Table 32.116 mRNA Vaccines and Therapeutics Market in Canada, till 2035 (USD Million)
Table 32.117 mRNA Vaccines and Therapeutics Market in Europe, till 2035 (USD Million)
Table 32.118 mRNA Vaccines and Therapeutics Market in Germany, till 2035 (USD Million)
Table 32.119 mRNA Vaccines and Therapeutics Market in the UK, till 2035 (USD Million)
Table 32.120 mRNA Vaccines and Therapeutics Market in France, till 2035 (USD Million)
Table 32.121 mRNA Vaccines and Therapeutics Market in Italy, till 2035 (USD Million)
Table 32.122 mRNA Vaccines and Therapeutics Market in Spain, till 2035 (USD Million)
Table 32.123 mRNA Vaccines and Therapeutics Market in Belgium, till 2035 (USD Million)
Table 32.124 mRNA Vaccines and Therapeutics Market in Asia-Pacific, till 2035 (USD Million)
Table 32.125 mRNA Vaccines and Therapeutics Market in China, till 2035 (USD Million)
Table 32.126 mRNA Vaccines and Therapeutics Market in India, till 2035 (USD Million)
Table 32.127 mRNA Vaccines and Therapeutics Market in Japan, till 2035 (USD Million)
Table 32.128 mRNA Vaccines and Therapeutics Market in Australia, till 2035 (USD Million).
Table 32.129 Concluding Remarks: Overall Market Landscape.
Table 32.130 Concluding Remarks: Partnerships and Collaborations.
Table 32.131 Concluding Remarks: Funding and Investment Analysis.
Table 32.132 Concluding Remarks: Clinical Trial Analysis.
Table 32.133 Concluding Remarks: Patent Analysis.
Table 32.134 Concluding Remarks: Market Forecast and Opportunity Analysis
Please reach out to our team for more details.